High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms-Reference-Cited by-同舟云学术

High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms

Published:2015-07 Issue:7 Volume:32 Page:637-649
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

McPhee Fiona,Suzuki Yoshiyuki,Toyota Joji,Karino Yoshiyasu,Chayama Kasuaki,Kawakami Yoshiiku,Yu Min Lung,Ahn Sang Hoon,Ishikawa Hiroki,Bhore Rafia,Zhou Nannan,Hernandez Dennis,Mendez Patricia,Kumada Hiromitsu

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-015-0221-5

Reference22 articles.

1. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment Web resource. Hepatology. 2014;59:318–27.

2. Ansaldi F, Orsi A, Sticchi L, Bruzzone B, Icardi G. Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol. 2014;20:9633–52.

3. World Health Organization. Hepatitis C Key Facts. WHO factsheet No 164. 2014. http://www.who.int/mediacentre/factsheets/fs164/en/ . Accessed Apr 2015.

4. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96–100.

5. McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012;56:5387–96.

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease;The Korean Journal of Internal Medicine;2022-09-01

2. Hepatitis C virus (HCV) : Development of anti-HCV agents and anti-HCV therapy;Okayama Igakkai Zasshi (Journal of Okayama Medical Association);2020-12-01

3. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population;Journal of the Formosan Medical Association;2020-06

4. Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir;Journal of Human Genetics;2019-10-23

5. Developments in the treatment of HCV genotype 3 infection;Expert Review of Anti-infective Therapy;2019-10-03